Clinical and Laboratory Characteristics of Clostridium difficile Infection in Patients with Discordant Diagnostic Test Results

Anna
The aim of this study was to compare the clinical and laboratory characteristics of Clostridium difficile infection (CDI) in patients with discordant test results for the cytotoxin assay (CYT) and PCR assays. A retrospective study from May to August 2008 and March to May 2010 was performed. CDI was diagnosed in 128 patients. PCR increased the yield of C. difficile cases by 2-fold compared to that of the CYT assay. Fifty-six cases (44%) were detected by PCR only (CYT negative). Forty-nine percent of patients with non-NAP1 strains were detected by PCR only, compared to 28% of those infected with NAP1 strains (P < 0.05). No significant differences were found in the clinical severity of illness and outcome among patients that tested positive for CDI by both tests (CYT and PCR) compared to those that tested positive by PCR only.
C
lostridium difficile has been implicated in up to 25% of antibiotic-associated diarrhea and nearly all bacterial cases of hospital-acquired diarrhea (6, 10) . The spectrum of disease can range from uncomplicated diarrhea to pseudomembranous colitis, toxic megacolon, sepsis with associated organ failure, and even death. North American hospitals began to experience an increased incidence of a particularly virulent strain of C. difficile in the early part of the decade, characterized by recurrent infection and increased mortality, especially in the elderly (3, 8, 11, 14, 20) .
The increase in the incidence of C. difficile infection (CDI) has been attributed in part to the emergence of a predominant strain, known as North American pulsed-field type 1 (NAP1), of ribotype 027 and group BI. The characteristics of the NAP1 strain include fluoroquinolone resistance, production of binary toxin in addition to toxins A and B, and various polymorphisms in the tcdC gene (13) . Louie et al. were recently able to demonstrate both an increased severity of illness due to the NAP1 strain and lower incidence of relapse in those treated with fidaxomicin who were infected with non-NAP1 strains, suggesting that knowledge of the infecting strain may have a significant impact on treatment decisions (9) . One of the FDA-cleared PCR diagnostic assays for the detection of C. difficile, the Xpert (Cepheid, Sunnyvale, CA), is able to identify NAP1 strains in a timely fashion; although only FDA cleared for infection control purposes, such results may potentially be used to make therapeutic decisions.
Toxigenic culture has been considered the gold standard for the diagnosis of C. difficile, and its use is supported by the most recent practice guidelines issued by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) (4). However, toxicogenic culture is time consuming and labor intensive. Alternative enzyme immunoassay (EIA)-based tests are more frequently used for routine diagnostic use, but sensitivities for EIAs have been reported to be as low as 30% (15) . PCR-based detection of C. difficile is increasingly being used in many centers. PCR is rapid and highly sensitive but detects the DNA of the toxigenic strain of C. difficile and not the toxin itself; therefore, the clinical specificity of this test needs further investigation.
We undertook a study to understand the clinical and epidemiological impact of transitioning from the cytotoxin assay (CYT) to PCR testing for the diagnosis of CDI in a major academic medical center. We examined the performance of CYT and PCR by symptoms and severity, including the absence or presence of diarrhea, along with associated symptoms and laboratory characteristics of CDI and clinical outcomes. Routine diagnosis of C. difficile during the study period was performed using a two-step algorithm that included an enzyme immunoassay (EIA) for the detection of the C. difficile common antigen glutamate dehydrogenase (GDH), followed by the CYT assay. Physicians were not aware of the corresponding PCR results during the study period. Unlike the GDH-CYT assay, PCR was not performed in real time but within 7 days of sample collection. GDH and cytotoxin assay. The GDH assay was performed using the manual GDH EIA C. DIFF CHEK-60 (Techlab, Blacksburg, VA), following the manufacturer's instructions and as previously reported (1) . The final optical intensities of the reactions were read at 450 nm on the Bio-whittaker 2001 microplate reader (Biowhittaker Molecular Applications, Inc., Walkersville, MD) against a blank at 620 nm. All GDH-positive stool specimens were subjected to the cytotoxin neutralization assay, which was performed as previously reported (1) .
MATERIALS AND METHODS
PCR assay. For stool samples tested from May to August 2008, a realtime PCR assay that detects four C. difficile genes encoding toxins A (tcdA) and B (tcdB) and the binary toxin genes (cdtA and cdtB) was used. Testing was performed as previously described by Wroblewski et al. on the ABI 7500 FAST platform (22) . For samples tested from March to June 2010, the Cepheid Xpert C. difficile/epi PCR (Cepheid, Sunnyvale, CA) was used. This multiplex real-time PCR detects the toxin B gene (tcdB), the binary toxin gene (cdt), and the tcdC gene deletion at nucleotide 117. The Xpert C. difficile/epi PCR (Xpert PCR) was performed according to the manufacturer's instructions and run on the GeneXpert instrument. A small aliquot of stool sample received in the laboratory was transferred into the sample reagent vials using the Cepheid collection device (Copan swabs). The sample reagent vials were vortexed for 10 s, and a Pasteur pipette was used to transfer the sample into the S chamber of the cartridge, which was then placed on the GeneXpert instrument, and the test was performed using the GeneXpert C. difficile assay program.
The cycle threshold (C T ) value, the PCR cycle where enough DNA amplification has occurred for a fluorescence signal to be detected (21) , was used as a marker of C. difficile burden. The C T was recorded and the mean and standard deviation calculated for samples positive by both CYT and PCR versus those that were positive by PCR only.
NAP1 characterization. Identification of the NAP1 strain was achieved via sequencing of the tcdC gene (tcdC gene deletion at nucleotide 117) in both study periods. For the 2010 study period, testing was facilitated by presumptive identification of NAP1 strains by the Cepheid Xpert C. difficile/epi PCR. Sequencing of the tcdC gene was carried out after purifying DNA from C. difficile colonies; the tcdC gene was amplified using primers C1 and C2, as described by Spigaglia and Mastrantonio (16) . The PCR products were run on a 1.2% agar gel, and the ϳ800-bp band gel purified and submitted for sequencing at the MSKCC DNA Sequencing Core Facility.
PCR-ribotyping was performed as previously described by Bidet et al. (2) . Genomic DNA was isolated from C. difficile colonies growing on a C. difficile selective agar plate (CDSA; BD BBL, Sparks, MD), amplified, and fractionated on a 3% Amresco agarose plate (Fisher Scientific, Fairlawn, NJ) for 6 h at 85 V and 4°C in Tris-borate-EDTA buffer. Images of the gels were captured using a Gel Doc 2000 system (Bio-Rad Laboratories, Hercules, CA) after staining with ethidium bromide. The ATCC strain BAA-1805 (C. difficile; NAP1, toxinotype III, binary toxin positive) was included as a reference strain in all gels.
Clinical data. For both time periods, C. difficile cases were defined as having clinical symptoms (diarrhea, fever, abdominal pain, and leukocytosis) with a positive PCR or a positive CYT assay. A retrospective chart review was conducted for all positive specimens, where clinical, laboratory, and demographic data were extracted from the computerized MSKCC clinical information system. Demographic data included age and sex. Clinical data included past medical history, any history of CDI in the MSKCC system, inpatient status, type of malignancy, number of hospitalizations in the previous year, history of chemotherapy within 30 days prior to CDI, history of surgery within 60 days prior to CDI, and if so, whether the surgery involved the gastrointestinal tract. For clinical presentation, the presence of fever, abdominal pain, or diarrhea at the time of C. difficile-associated diarrhea (CDAD) diagnosis was recorded. Laboratory data included white blood cell (WBC) count and the presence of colitis on imaging within 48 h of diagnosis. The hospital course was also followed, with particular attention to the presence of sepsis (as defined by the treating physician), intensive care unit (ICU) admission, ICU length of stay (LOS), total LOS, and LOS before and after CDI diagnosis. Recurrence of CDI more than 2 weeks after the index episode and within 1 year of diagnosis, as well as 30-day mortality, was recorded.
The severity of CDI was assessed using a 3-tiered scoring system, with 19%) were diagnosed among 408 patients tested during the 2010 study period. Among the isolates, 29/128 (23%) were NAP1 strains for both study periods. The incidence of NAP1 fell from 32% (16/50) of all strains tested during the 2008 period to 17% (13/78) during the 2010 period; this was a statistically significant difference (P ϭ 0.046). The overall incidence of CDI during the two study periods was 24.97 per 10,000 patient days in May to August 2008 and 16.84 per 10,000 patient days in March to May 2010.
RESULTS
CDI was diagnosed in
A separate analysis of clinical outcomes in the 2008 versus 2010 cohorts was conducted, with no statistically significant differences noted in clinical or demographic characteristics or major outcomes, such as median WBC count, LOS, colitis, septic shock, severity level, symptomatology, or recurrence rate. There was also no statistically significant difference in CYT/PCR discordant test results between the two study periods (43% in 2010 versus 44% in 2008) despite the different PCR methodologies used. This led us to combine the data for the two cohorts despite differences in test methodology and incidence rates for the two time periods, as noted above.
Demographic characteristics and underlying disease. The demographic characteristics of the 128 patients included in the study are shown in Table 1 . The mean age of the patients was 52 years. Fifty-six percent (72/128) were males and 23% (29/128) were less than 18 years of age. Fifty percent (64/128) of patients had underlying liquid tumors; among patients with solid tumors, 26/64 (40%) had undergone surgery within 30 days prior to the diagnosis of CDI. Sixty-nine (54%) patients had received chemotherapy in the 30 days prior to developing CDI. The mean number of hospitalizations of the cohort prior to developing CDI was 2 (range 0 to 11). Thirty-five (27%) patients had a history of CDI.
Clinical characteristics. The primary clinical indication for testing was diarrhea (108/128; 84% of patients had diarrhea). Additional clinical indications included fever and abdominal pain (5), nausea and vomiting (3), abdominal pain alone (2), leukocytosis (2), sepsis (2), and fever alone (1). Three patients had stool samples sent because they had a history of CDI; indications for testing were unknown for 2 patients.
Cytotoxin and PCR positive versus PCR positive only. Among the study cohort, 56 patients were positive by PCR only compared to 72 patients whose samples were positive by both CYT and PCR. Among 29 NAP1 strains, 21 (72%) were detected by both assays, whereas among the non-NAP1 strains, 51 of 99 (52%) patients were positive by both assays (P Ͻ 0.05). Except for a preponderance of males in the CYT-positive/PCR-positive group, the underlying and demographic characteristics among the two groups were similar, as shown in Table 1 . Cases positive by both assays were more likely to have had a history of CDI. No statistically significant difference was detected in the clinical presentation (symptoms and WBC count) at the onset of infection and severity (as assessed by ICU admission, sepsis syndrome, 30-day mortality, and presence of colitis on imaging). However, recurrence of CDI was more common in patients when both assays were positive than when only PCR was positive (31% versus 14%; P ϭ 0.03).
One patient was positive by CYT but negative by PCR and was excluded from the analysis due to a concern for false-positive CYT results.
Clinical outcome of PCR-positive patients who did not receive treatment for CDAD. At the time of the study, treating physicians were not made aware of PCR results if their patients' samples were PCR positive but CYT negative. Among the 56 patients that were positive by PCR only, 23 did not receive any treatment; the others received empirical treatment for CDI. Complete treatment records were available for 26/33 patients; the mean duration of treatment was 7.5 days and the median was 7 days. Among the 23 that were untreated, 15 (65%) patients had diarrhea on the day stool sample was tested. Thirty-five percent of patients were hematopoietic stem cell transplant recipients. Two of 23 had a history of CDI, and 3/23 suffered from a recurrence of CDI (average time between episodes, 5 months; range, 4 to 6 months). The isolates from 3 patients with recurrent episodes were further evaluated by PCR-ribotyping to determine genetic relatedness and were found to be identical in all 3 cases (Fig. 1 ). Among the 23 untreated patients, 4 were infected with the NAP1 strain. Ten of the 23 patients died due to progression of underlying cancer; no deaths were attributed to C. difficile.
PCR assay characteristics. In study period 1, the average C T value for the tcdB gene target for patients with samples testing positive by both PCR and CYT was 21.24 (range, 13.68 to 31.44), while the average C T value for patients with PCR-positive but CYT-negative samples was 25.79 (range 19.39 to 34.14). The difference between the two means was significant (P Ͻ 0.001) (Fig. 2A) . In study period 2, the average C T value for patients The difference between the two means was significant (P Ͻ 0.001) (Fig. 2B) .
DISCUSSION
Several commercial real-time PCR assays for the detection of toxigenic C. difficile have become available recently and are being increasingly implemented for routine diagnostic use (7, 12, 17) . These molecular assays have increased sensitivity compared to the sensitivities of the widely used enzyme immunoassays (EIA), as well as the current gold standard cell culture cytotoxin (CYT) assays. However, there are several concerns associated with the transition to PCR-based testing for C. difficile: first, the clinical sensitivity of the test is called into question, as a consequence of an increase in the detection of both true CDI and cases of colonization. Second, there is uncertainty regarding the impact of PCRbased diagnostic methods on local epidemiology and in outlining the distinction between a true versus a pseudo-outbreak as a result of increased detection.
In our study, we found an increase in the sensitivity of PCR for non-NAP1 strains compared to its sensitivity for NAP1 strains. Seventy-two percent of all NAP1 strains were detected by CYT assay, compared to 51% of non-NAP1 strains. This is perhaps explained by the increase in toxin production associated with the NAP1 strain as opposed to non-NAP1 strain types, as described by Warny et al. (20) . The higher toxin production would result in increased detection of cytopathic effect in cells used in the CYT assay compared to the detection of strains with less toxin production. A previous study by Tenover et al. reported a similar observation that the Xpert PCR assay was more sensitive than the CYT assay for detecting all strains of C. difficile except for NAP-1 strains (for which sensitivity was equivalent) (19) .
All stool samples tested in our series were from patients with some clinical indication for CDI, including but not limited to diarrhea, leukocytosis, fever, or abdominal pain. Patients who tested positive by both assays were more likely to have both prior and recurrent episodes of CDI (P Ͻ 0.02), probably due to a higher organism burden. We found that CDI cases detected by PCR only had significantly lower copy numbers of the toxin B gene than cases that were detected by both assays. These findings remained significant regardless of the PCR method used ( Fig. 2A  and B) .
In terms of the clinical sensitivity of the test, no significant differences were found in CDI symptoms and severity between the two groups; specifically, 85% of patients who tested positive by both assays and 84% of cases that were detected by PCR only reported symptoms of diarrhea. No statistically significant differences between the two groups were observed in other clinical parameters and laboratory characteristics, suggesting that PCR is not an overly sensitive test in persons who have clinical indications for C. difficile testing. Thirty-three of 56 cases that were detected by PCR only received treatment due to high clinical suspicion for CDI, although the clinicians were not aware of the PCR results. Among the remaining 23 patients who did not receive treatment, 15 reported symptoms of diarrhea. These patients perhaps had mild CDI that resolved without treatment. Three of 23 (13%) patients that did not receive treatment had a symptomatic relapse with the original infecting strain, as demonstrated by DNA fingerprinting (Fig. 1) .
Our study has several limitations, including its retrospective design and the limitations inherent in conducting chart reviews (5) . The retrospective design and limitations of our electronic charting system also restricted our ability to gather certain potentially useful data, such as frequency and character of stools. We used different real-time PCR methodologies in the two study periods, although the target gene (tcdB) for both assays was the same. We used different testing methods to detect recurrence in the two study periods, although the proportions of clinical relapse were not significantly different (20% in 2008 and 26% in 2010; P value is nonsignificant). We do not think this limits the findings of our study.
To summarize, our study furthers the understanding of the clinical and epidemiological impact of PCR testing for CDI. In patients with clinical indications for CDI testing, PCR increased the yield of C. difficile cases by 2-fold compared to the results with the cytotoxin assay, and this increase was most significant for non-NAP1 strains. We did not observe significant differences in symptoms and severity of CDI cases between patients that tested positive by both assays compared to those who tested positive by PCR only. We did find a higher toxin gene burden in cases that tested positive by both assays and, also, a higher likelihood of relapse.
For laboratories transitioning to PCR-based testing, the emphasis should be on testing only diarrheal stools (or when additional clinical indications are present) as defined in the most recent guidelines from the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America (4) . As more patients with CDI are detected and treated based on PCR results, additional prospective studies are needed to understand the long-term impact of molecular-based testing on the control of C. difficile.
